Special Issue "How Has COVID-19 Impacted the Allergic Disease and Health?"
Deadline for manuscript submissions: 20 January 2023 | Viewed by 14
As of June 2022, the SARS-Cov-2 virus is responsible for 541 million confirmed cases and more than 6,300,000 deaths worldwide, pushing healthcare systems to their limit. The clinical features of COVID-19 are diverse, ranging from asymptomatic to critical illness and death for high risk patients with comorbidities.
As a multisystemic inflammatory disease with wide spectrum of clinical presentations, COVID-19 presents a huge challenge for the medical community.
Allergic diseases, such as asthma, rhinosinusitis, atopic dermatitis, chronic urticaria, etc., are important causes of morbidity and increase the demand on healthcare services worldwide, leading to considerable cost burden. Thus, correct diagnosis and appropriate treatment are of utmost importance during the pandemic.
To date, there have been many published articles on the effects of COVID-19 in allergic patients. Although there is a clear correlation between viral infections and exacerbation of allergic diseases, regarding SARS-Cov-2 infection, several studies have shown that allergy is not a risk factor for COVID-19. In addition, there are no data showing deterioration of allergic disease as a result of COVID-19 infection. The treatment of allergic reactions to vaccines against SARS-Cov-2 is of particular interest.
There is also evidence that genetic predisposition to any allergic disease may be associated with lower susceptibility to COVID-19. The presence of allergic disease may protect COVID-19 patients from severe disease.
This Special Issue aims to present the impact of COVID-19 infection in different allergic diseases, regarding susceptibility and severity of both the infection and the allergy.
The study of interaction between COVID-19 infection and allergy should benefit from all recent data collected on the subject and will give us a clearer view of the potential interactions between allergic diseases and COVID-19.
We are soliciting articles that discuss the impact of COVID-19 on allergic diseases, including topics such as:
- Asthma in children and adults and different endotypes;
- Atopic dermatitis;
- Biologic agents for allergic diseases and COVID-19;
- Drug allergy and vaccination against Sars-Cov-2;
- Type 2 inflammation and COVID-19 infection.
Dr. Giannis D. Paraskevopoulos
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Allergies is an international peer-reviewed open access quarterly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- allergic diseases